Skip to main content
Ovation Science Inc. logo

Ovation Science Inc. — Investor Relations & Filings

Ticker · OVAT ISIN · CA69016D1087 LEI · 549300A1P7L8HTTQXY56 CSE Professional, scientific and technical activities
Open in API
Filings indexed 252 across all filing types
Latest filing 2020-06-02 Interim / Quarterly Rep…
Country CA Canada
Listing CSE OVAT

About Ovation Science Inc.

https://ovationscience.com/

Ovation Science Inc. is a research and development company specializing in advanced topical and transdermal product formulations. The core technology is Invisicare®, a patented, high-performance drug delivery system engineered to enhance the penetration and efficacy of active ingredients, particularly cannabis and hemp-derived cannabinoids (CBD, THC, CBN, CBG). Ovation utilizes pharmaceutical protocols to develop these formulations. Its primary business model involves licensing the Invisicare® technology and proprietary formulations to international partners for manufacturing and market distribution. The company also distributes finished topical CBD products under proprietary brands, such as the Invibe® MD wellness line and ARLO CBD Beauty anti-aging line, all leveraging the unique delivery capabilities of Invisicare®.

Recent filings

Filing Released Lang Actions
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management Discussion & Analysis For the three months ended March 31, 2020 and 2019' and contains detailed discussion of the company's business, regulatory environment, and forward-looking statements. It references condensed consolidated interim financial statements for the three months ended March 31, 2020, indicating it is a quarterly or interim report. The content includes substantive financial and operational analysis, consistent with a Management Discussion and Analysis (MD&A) section typically found in interim or quarterly reports. The document length is substantial (15,000 characters), and it contains actual financial and business discussion rather than just an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2020
2020-06-02 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification by the CEO of Ovation Science Inc. regarding the interim financial report and interim MD&A for the period ended March 31, 2020. It is a Form 52-109FV2 Certification of Interim Filings for a Venture Issuer. The content is primarily an officer certification confirming the accuracy and fair presentation of the interim filings, without containing the actual financial data or detailed financial statements. According to the Certification Rule, documents that are primarily officer certifications, even if referencing interim reports, should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (3043 characters), and it does not contain substantive financial data or analysis, so it is not an Interim Report (IR). Therefore, the correct classification is Regulatory Filings (RNS).
2020-06-02 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification letter by the CFO of Ovation Science Inc. regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended March 31, 2020. It is a Form 52-109FV2 Certification of Interim Filings for a Venture Issuer. The document does not contain actual financial data or the interim report itself, but rather certifies the accuracy and completeness of such filings. According to the Certification Rule, documents that are primarily officer certifications or attestations, even if referencing interim reports, should be classified as Regulatory Filings (RNS). The document length is 3045 characters, which is relatively short and consistent with a certification letter rather than a full interim report. Therefore, the correct classification is Regulatory Filings (RNS).
2020-06-02 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management Discussion & Analysis For the three months ended March 31, 2020 and 2019' and contains detailed discussion of the company's business, regulatory environment, and forward-looking statements. It references condensed consolidated interim financial statements for the three months ended March 31, 2020, indicating it is a quarterly or interim report. The content includes substantive financial and operational analysis, consistent with Management Discussion & Analysis (MD&A) sections typically found in Interim/Quarterly Reports. The document length is substantial (15,000 characters), and it contains actual financial and business data, not merely an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2020
2020-06-02 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification form (Form 52-109FV2) signed by the CEO certifying the accuracy and fair presentation of the interim financial report and interim MD&A for the period ended March 31, 2020. It explicitly states it is a certification of interim filings and does not contain the actual financial data or analysis itself. The document is short (3043 characters) and serves as an officer attestation rather than the interim report itself. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as an Interim Report (IR).
2020-06-02 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification letter by the CFO of Ovation Science Inc. regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended March 31, 2020. It is a Form 52-109FV2 Certification of Interim Filings for a Venture Issuer. The document does not contain actual financial data or the interim report itself, but rather certifies the accuracy and completeness of the interim filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) itself. The document length is short (3045 characters), consistent with a certification letter rather than a full report.
2020-06-02 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.